Literature DB >> 12167622

Localization of the thyroid peroxidase autoantibody immunodominant region to a junctional region containing portions of the domains homologous to complement control protein and myeloperoxidase.

Jin Guo1, Sandra M McLachlan, Basil Rapoport.   

Abstract

Thyroid peroxidase (TPO) autoantibody epitopes are largely restricted to an immunodominant region (IDR) on the extracellular region of the native molecule. Localization of the IDR has been a longstanding and difficult goal. The TPO extracellular region comprises a large myeloperoxidase-like domain, linked to the plasma membrane by two smaller domains with homology to complement control protein (CCP) and epidermal growth factor (EGF), respectively. Recent studies have focused on the CCP- and EGF-like domains as the putative location of the TPO autoantibody IDR. To address this issue, we attempted to express on the surface of transfected cells native TPO in which the CCP- and EGF-like domains were deleted, either together or individually. We used a quartet of human monoclonal autoantibodies that define the TPO IDR, as well as polyclonal TPO autoantibodies in patients' sera, to detect these mutated TPO molecules by flow cytometry. The combined CCP/EGF-like domain deletion did not produce a signal with TPO autoantibodies but did not traffic to the cell surface. In contrast, both monoclonal and polyclonal autoantibodies recognized TPO with the juxtamembrane EGF-like domain deleted equally as well as the wild-type TPO on the cell surface. TPO with the CCP-like domain deleted expressed normally on the cell surface, as determined using the polyclonal mouse antiserum. Nevertheless, this modified TPO molecule was recognized very poorly by both the human monoclonal autoantibodies and the polyclonal autoantibodies in patients' sera. In conclusion, we have clearly excluded the juxtamembrane EGF-like domain as being part of the IDR. In contrast, a component of the CCP-like domain does contribute to the IDR. These data, together with findings from other studies, localize the TPO autoantibody IDR to the junction of the CCP-like domain and the much larger myeloperoxidase-like domain on TPO.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167622     DOI: 10.1074/jbc.M205524200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Thyroid peroxidase forms thionamide-sensitive homodimers: relevance for immunomodulation of thyroid autoimmunity.

Authors:  David O McDonald; Simon H S Pearce
Journal:  J Mol Med (Berl)       Date:  2009-08-08       Impact factor: 4.599

2.  Evaluation of conformational epitopes on thyroid peroxidase by antipeptide antibody binding and mutagenesis.

Authors:  M Gora; A Gardas; W Wiktorowicz; P Hobby; P F Watson; A P Weetman; B J Sutton; J P Banga
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

3.  Localization of the immunodominant region on human thyroid peroxidase in autoimmune thyroid diseases: an update.

Authors:  Damien Bresson; Sandra A Rebuffat; Sylvie Péraldi-Roux
Journal:  J Autoimmune Dis       Date:  2005-03-15

4.  Modelling of Thyroid Peroxidase Reveals Insights into Its Enzyme Function and Autoantigenicity.

Authors:  Sarah N Le; Benjamin T Porebski; Julia McCoey; James Fodor; Blake Riley; Marlena Godlewska; Monika Góra; Barbara Czarnocka; J Paul Banga; David E Hoke; Itamar Kass; Ashley M Buckle
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

Review 5.  Thyroid Autoantibodies Display both "Original Antigenic Sin" and Epitope Spreading.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Front Immunol       Date:  2017-12-20       Impact factor: 7.561

6.  A redundant role of human thyroid peroxidase propeptide for cellular, enzymatic, and immunological activity.

Authors:  Marlena Godlewska; Monika Góra; Ashley M Buckle; Benjamin T Porebski; E Helen Kemp; Brian J Sutton; Barbara Czarnocka; J Paul Banga
Journal:  Thyroid       Date:  2013-09-26       Impact factor: 6.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.